Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?
Key PointsIt's a cancer medication with immense potential.
В этом разделе статьи показаны на английском.
Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?
Редакция Trade News (2026-08-28) фиксирует рынок: Key PointsIt's a cancer medication with immense potential. Первоисточник — оригинал Nasdaq Market Structure (nasdaq.com).